Tagged with Europe

Opinion Nigel Hughes of the European Health Data & Evidence Network (EHDEN) outlines EHDEN’s scope and purpose and highlights why greater collaboration on real-world data (RWD) will be crucial to ensuring better global health outcomes.    Ultimately, EHDEN is striving to ensure 21st century research can be conducted with 21st century…

Europe The EFPIA’s Nathalie Moll outlines the case for a new EU-wide industrial strategy with biopharmaceuticals at its heart.   The pharmaceutical industry is an area of strategic economic and social value where the EU is a global player   Europe has a history as a world leader in medical innovation,…

Opinion Becton Dickinson’s Fiona Garín looks at the rise of Healthcare-Acquired Infections (HAIs) in Europe and how an industry-wide culture of safety needs to be developed to counter this growing threat.   Healthcare systems in Europe are becoming more complex in their quest to drive affordability, quality of care and patient…

Artificial Intelligence IBM Watson Health’s Director for Global Life Sciences & Go-To Market Leader for Europe & Asia Pacific Christina Busmalis gives her insights into how AI and greater utilisation of real-world evidence is shaping the global biopharmaceutical industry, including the tangible results she has seen so far, and the lengthy path…

Hungary Hungary’s two largest pharma firms, Egis Pharmaceuticals and Gedeon Richter, are stepping up their biosimilars offering; providing the European market with more affordable biologic medicines and bolstering Hungary’s footprint in biologics R&D.   Biosimilars in Europe Over the past decade, over 80 biologic molecules have been launched worldwide. By 2020…

Hungary Like many of its European counterparts, Hungary is suffering from medicine shortages. Vaccines, vitamins, and orphan drugs are some of the most affected areas and oncology patients are now also at risk.   An Increasing Burden Over 14,000 types of pharmaceuticals are unavailable in Hungarian pharmacies, which is placing an…

Europe Awareness is growing of the dangers of healthcare-associated infections (HAIs) in Europe, and conversations are beginning to taking place around how to leverage data to combat these infections and antimicrobial resistance (AMR). A panel of experts from diverse backgrounds at the European Health Forum Gastein put their heads together to…

Hungary Hungarian patients currently experience longer wait times and more limited access to subsidised innovative medicines than their neighbours in Bulgaria and Slovakia.leading some organisations to urge the government to increase funding and shorten approval times.   According to the Hungarian Association of Innovative Pharma Manufacturers, since 2016 only 48 new…

Pharma Market Poland is by far the largest pharma market in the Central and Eastern Europe (CEE) region, with a total value of EUR 6.352 billion for 2017. The Czech Republic is in second place, followed by Romania and Hungary Made with Visme Infographic Maker     The CEE countries that exported…

Generics Christoph Stoller, general manager for Austria and Germany at Teva was recently elected president of Medicines for Europe, the continent-wide association for the generics and biosimilars industries. Stoller plans to focus his efforts on improving access to generics and biosimilars in Europe, as well as tackling the damaging issue of…

Oncology Cancer is on the rise in Hungary and survival rates are considerably lower than the European average. The country’s innovative pharma association has taken the initiative to suggest measures that it believes would drastically improve cancer mortality rates and quality of life for oncology patients.   Recent statistics show that…

Europe Christoph Stoller, the recently appointed president of Medicines for Europe, outlines the mission of his presidency, how the association and its members are working to tackle the issue of drug shortages across the continent, and the crucial importance of establishing a high-level dialogue between industry and governments. Adrian van den…